The abstract is read at the publisher; the summary is JClub's.
MXC-017 (150 mg/kg) reduces severity of 3.5% DSS-induced colitis in C57BL/6 mice and restores intestinal barrier function, alongside improved weight recovery and colon preservation.
- Why it matters: Ulcerative colitis and radiation enteropathy feature epithelial injury, barrier dysfunction, and inflammation, yet effective therapies are limited.
- What they did: C57BL/6 mice received MXC-017 or vehicle during 3.5% DSS colitis and after 13 Gy total abdominal irradiation, with assessments of disease activity, permeability, inflammatory/epithelial markers, and histopathology.
- The result: MXC-017 lowered proinflammatory cytokines, macrophage infiltration, epithelial injury, and goblet cell loss in DSS colitis, and improved post-irradiation weight recovery and epithelial architecture, while not protecting prostate cancer stem cells from radiation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.